Skip to content
Menu

Genmab A/S GMAB

Full chart Compare
Set alert

Price alert · GMAB

All alert types
50.60 USD -0.75 (-1.46%)

Regular-session close

50.02 -0.58 -1.15%

After hours · Nov 20, 7:56 PM ET

50.24 Day range 51.72
23.85 52-week range 57.29
YTD
+64.29%
1 year
+68.44%

5D -1.88 (-3.57%)

5152MonTueWedThuFri50.74
Market cap
31.20B
Revenue (ttm)
4.30B
Profit margin
16.97%
EPS (ttm)
1.17
Shares out
616.59M
P/E ratio
43.25
Forward P/E
32.03
YTD return
+64.29%
1-year return
+68.44%
50-day average
42.62
Volume
2.90M
Avg volume
4.17M
Open
51.61
Previous close
51.35
Day's range
50.24 – 51.72
52-week range
23.85 – 57.29
Beta
0.52
Analysts
Strong Buy
Price target
65.01 (+28.5%)
Earnings date
Feb 16, 2027

Key statistics

200-day average
31.92
Enterprise value
35.83B
PEG ratio
4.61
Price / sales
7.26
Price / book
5.06
Revenue growth
16.10%
Free cash flow
854.88M
Total cash
1.87B
Total debt
5.20B
Return on equity
12.07%
Short % of float
1.59%

Fundamental scorecard

9 of 25 checks passed on GMAB’s reported financials

ValueGrowthProfitabilityHealthDividend

9of 25 checks passed

  • Value 1 of 5
  • Growth 4 of 5
  • Profitability 3 of 5
  • Financial health 1 of 5
  • Dividend No data

Statements to Sep 30, 2026.

Financials — quick view

All financials
GMAB Revenue — quarterly 1.19B
GMAB Net income — quarterly 342.00M
GMAB EPS — quarterly 0.558

Earnings

GMAB recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 16, 2027Dec 30, 20260.23———
Nov 5, 2026Sep 30, 20260.360.56+0.20+55.56%
Aug 6, 2026Jun 30, 20260.370.54+0.17+45.95%
May 7, 2026Mar 31, 20260.150.087-0.06-42.00%
Feb 17, 2026Dec 31, 20250.460.05-0.41-89.13%
Nov 6, 2025Sep 30, 20250.480.65+0.17+35.42%

Upgrades / downgrades

GMAB analyst upgrades and downgrades
DateFirmActionFromTo
Nov 13, 2026Morgan StanleymainEqual-WeightEqual-Weight
Oct 30, 2026Morgan StanleymainEqual-WeightEqual-Weight
Oct 30, 2026GuggenheimmainBuyBuy
Oct 29, 2026Truist SecuritiesreitBuyBuy
Oct 29, 2026HC Wainwright & Co.mainBuyBuy
Oct 26, 2026TD CowenmainBuyBuy

About Genmab A/S

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Sector
Healthcare
Industry
Biotechnology
Country
Denmark
Website
genmab.com

News

Your note

Sign in to keep a note on GMAB — it syncs with the Stock Master app.

Institution ownership

GMAB institution ownership
Holder% heldSharesValueReported
Darwin Global Management, Ltd.2.87%17,899,876905.73MSep 29, 2026
Paradigm Biocapital Advisors LP2.27%14,136,472715.31MSep 29, 2026
Orbis Allan Gray Ltd1.69%10,567,391534.71MSep 29, 2026
Deerfield Management Company, L.P1.10%6,865,000347.37MSep 29, 2026
Alliancebernstein L.P.1.03%6,403,228324.00MSep 29, 2026
Arrowstreet Capital, Limited Partnership0.97%6,069,276307.11MSep 29, 2026

Fund ownership

GMAB fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Biotechnology ETF0.69%4,322,251218.71MSep 29, 2026
First TRT Exch-Trd Fd.-First TRT NYSE Arca Biotechnology Index Fd.0.50%3,121,944157.97MSep 29, 2026
NEW PERSPECTIVE FUND0.49%3,078,594155.78MSep 29, 2026
Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund0.08%520,70026.35MJul 30, 2026
American Century ETF Trust-Avantis International Equity ETF0.08%500,71825.34MSep 29, 2026
Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund0.06%350,00017.71MJul 30, 2026